)
Lexeo Therapeutics (LXEO) investor relations material
Lexeo Therapeutics Q3 2026 & Study result earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
HEROIC-PKP2 interim data across 10 participants showed reduced arrhythmia burden and potential improvement in cardiac function; LX2020 was generally well tolerated.
High-dose participants had mean reductions of 80% in NSVT burden and 44% in PVC burden at latest assessment; five of seven reported symptom improvement.
FDA is open to guideline-defined NSVT as a primary surrogate endpoint for a potential accelerated-approval study.
Q3 net loss was $38.3M; cash, cash equivalents and Treasury investments totaled $219.1M at September 30, with runway expected into 2028.
Financial highlights
Q3 revenue was $0; operating expenses were $40.4M versus $21.6M, and net loss was $38.3M versus $20.3M year over year.
Q3 R&D was $34.5M versus $15.7M; the increase largely reflected Mantle acquisition costs and an LX2006 milestone. G&A was $5.9M versus $6.0M.
9M operating expenses were $90.8M versus $86.1M; net loss was $84.4M versus $79.0M, including $9.9M of acquired IPR&D expense in 2026.
9M R&D was $69.2M versus $47.6M; G&A was $21.5M versus $38.6M.
Outlook and guidance
LX2020 pivotal-study initiation is targeted for H2 2027, with estimated enrollment of 60–80 participants and NSVT as the proposed primary surrogate endpoint.
Proposed accelerated-approval analysis would assess the proportion of patients below one NSVT episode per day at 12 months.
FDA discussions on study design, statistical analysis and confirmatory evidence are expected to continue into H1 2027; a controlled design is considered feasible.
Cash, cash equivalents and investments are expected to fund planned operations into 2028; spending is expected to rise as trials and capabilities advance.
Longer-term follow-up is intended to assess clinical endpoints for potential full approval, including PVC burden and ICD events.
- A $300 million shelf supports future offerings as two gene therapy programs advance clinically.LXEO
Registration filing - LX2020’s upcoming readout will focus on durable, clinically meaningful NSVT reduction.LXEO
Investor update - LX2006 milestones extend through 2028 as Q4 PKP2 data approach.LXEO
Chardan's 10th Annual Healthcare Conference - Pivotal and phase I gene therapy programs advance with major data and regulatory milestones ahead.LXEO
2026 Global Healthcare Conference - Pivotal FA and PKP2 gene therapy programs advance with strong data, broad pipeline, and robust cash runway.LXEO
Stifel 2026 Virtual Cardiometabolic Forum - Gene therapy programs advance with strong clinical data, scalable manufacturing, and commercial readiness.LXEO
12th Annual Cantor Fitzgerald Global Healthcare Conference - Acquisition expands the FA platform with multimodal therapies and $21.3M in payments.LXEO
M&A announcement - Gene therapies for rare cardiac diseases advance with strong data, pipeline, and financial runway.LXEO
Corporate presentation - LX2006 pivotal trial and LX2020 RMAT status drive progress; cash runway extends into 2028.LXEO
Q2 2026
)
)
)
)
)
)
)
)